Vancouver, British Columbia, August 13, 2020 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that it has been performing user testing with human subjects in Vancouver, BC with its version 2.0 THC Breath Analyzer (“THCBA”). The THCBA device currently provides results in under five minutes. Cannabix has been testing the THCBA device with positive and negative cannabis breath samples with the objective of further training the device’s machine learning database and optimizing components for its upcoming (more robust) version 3.0 device. In recent weeks, Company engineers have also been focusing on device scalability, reducing device production costs, and have tested new thermoplastic soft molded components that would allow for higher durability, and reproducibility. Additional sensors are being incorporated into the device that will integrate more breath sample meta-data and will allow for device usage under a wider range of environmental conditions. Engineers have also developed a technique for sanitization of the device between users, and the GUI for the device has been simplified for administrators. Many of these improvements have been incorporated into the current device and other improvements are scheduled to be included into a version 3.0 device that will undergo more widespread pilot use. Recent pictures of user testing activity with the THCBA version 2.0 are included in this press release and available on the Company’s website
Testing with subject
The user testing procedure includes a baseline breath sample prior to the subject smoking cannabis followed by samples taken after smoking cannabis at multiple time points up to a minimum of 2 hours. Newly available images show how a subject interacts with the device at various stages of use. The testing process includes a sampling stage, an analysis stage, and the results stage - showing when THC is detected (a positive result) and when THC is not detected (a negative result).
The THCBA incorporates microfluidic sensor technology for the detection of THC from breath. The Company has been developing the THCBA with Dr. Mina Hoorfar at University of British Columbia Okanagan campus (“UBC”) and has an exclusive technology license agreement with UBC. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment.
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.